|
|
|
|
| With over 450 unique products in clinical development and 50 anticipated approvals by 2030, the evolving regulatory landscape for cell and gene therapies is more critical than ever. Don't miss your chance to gain expert insights! Join the next Cell & Gene Live for an exclusive digital panel discussion exploring forward-looking perspectives on this transformative field. Registration is free—thanks to the support of Thermo Fisher Scientific. |
|
|
FOCUS ON REGULATORY & COMPLIANCE |
|
|
|
By Erin Harris, Editor-In-Chief, Cell & Gene | Leaders from Kiji Therapeutics, Precision Biosciences, and Orgenesis weigh in on what will likely accelerate the development of novel treatments, potentially revolutionizing patient care across a wider range of diseases and bringing the promise of personalized medicine closer to reality in 2025 and beyond. |
|
|
|
|
| Three Vital Steps To QMS Implementation | Article | MasterControl, Inc. | When selecting a QMS, it may feel like the most challenging step is making the purchase. This is not necessarily the case. Read more about the challenges of implementing an effective QMS. |
|
|
| Navigating Regulatory Challenges In Oligonucleotide Therapeutics | Article | By Kaitlyn Rouillard Vargas, Ph.D., Kymanox Corporation | Oligonucleotide therapies offer precise treatments for genetic disorders and chronic diseases. They face unique regulatory challenges but hold great promise, especially when combined with FDA engagement. |
|
|
|
REGULATORY & COMPLIANCE SOLUTIONS |
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
